UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053122
Receipt number R000060620
Scientific Title Verification of Colorectal Cancer Recurrence Prediction and Screening Capability Through Methylation Analysis of DNA in Plasma of SETOCHI Study Participants
Date of disclosure of the study information 2023/12/15
Last modified on 2023/12/15 17:53:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification of Colorectal Cancer Recurrence Prediction and Screening Capability Through Methylation Analysis of DNA in Plasma of SETOCHI Study Participants

Acronym

SETOUCHI-Liquid Biopsy Study

Scientific Title

Verification of Colorectal Cancer Recurrence Prediction and Screening Capability Through Methylation Analysis of DNA in Plasma of SETOCHI Study Participants

Scientific Title:Acronym

SETOUCHI-Liquid Biopsy Study

Region

Japan


Condition

Condition

Colorectal Cancer

Classification by specialty

Gastroenterology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

This study aims to develop a 'Methylated CpG, micro RNA, and long non-coding RNA (lncRNA) Detection Platform' that does not rely on NGS, by utilizing biomarkers such as methylation CpG sites, micro RNA, and noncoding long fragment RNA, which are frequently observed in specific types of cancer. The goal is to verify the effectiveness of recurrence prediction and screening following curative resection of gastrointestinal cancers, and to construct new cancer detection technology.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Verification of the effectiveness of recurrence prediction and early screening after curative resection, based on analysis results from Hi-SA method (Fragment Assay), DNA Chip (Gene Silicon), dPCR (QuantStudio Absolute Q Digital PCR System), and real-time PCR.

Key secondary outcomes

1) Setting the cutoff values in Hi-SA method (Fragment Assay), DNA Chip (Gene Silicon), dPCR (QuantStudio Absolute Q Digital PCR System), and real-time PCR.
2) Elucidation of the interrelationships in the results of Hi-SA method (Fragment Assay), DNA Chip (Gene Silicon), dPCR (QuantStudio Absolute Q Digital PCR System), and real-time PCR.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Targeting participants who participated in the SETOUCHI Study.

Key exclusion criteria

None

Target sample size

452


Research contact person

Name of lead principal investigator

1st name Takeshi
Middle name
Last name Nagasaka

Organization

Kawasaki Medical School

Division name

Advanced Oncology

Zip code

7010192

Address

577, Matsushima, Kurashiki-city, Okayama

TEL

0864621111

Email

takeshin@med.kawasaki-m.ac.jp


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Nagasaka

Organization

Kawasaki Medical School

Division name

Advanced Oncology

Zip code

7010192

Address

577, Matsushima, Kurashiki-city, Okayama

TEL

0864621111

Homepage URL


Email

takeshin@med.kawasaki-m.ac.jp


Sponsor or person

Institute

Kawasaki Medical School

Institute

Department

Personal name

Takeshi Nagasaka


Funding Source

Organization

kawasakiMedical School

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kawasaki Medical School

Address

577, Matsushima, Kurashiki-city, Okayama

Tel

0864621111

Email

takeshin@med.kawasaki-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2013 Year 12 Month 15 Day

Date of IRB


Anticipated trial start date

2023 Year 12 Month 15 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry

2026 Year 03 Month 31 Day

Date trial data considered complete

2026 Year 03 Month 31 Day

Date analysis concluded

2026 Year 03 Month 31 Day


Other

Other related information

This trial is an observational study


Management information

Registered date

2023 Year 12 Month 15 Day

Last modified on

2023 Year 12 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060620


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name